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Maternally transferred immunity can have a fundamental effect on the ability of offspring to deal with
infection. However, levels of antibodies in adults can vary both quantitatively and qualitatively between
individuals and during the course of infection. How infection dynamics and their modiﬁcation by drug
treatment might affect the protection transferred to offspring remains poorly understood. Using the
rodent malaria parasite Plasmodium chabaudi, we demonstrate that curing dams part way through
infection prior to pregnancy can alter their immune response, with major consequences for offspring
health and survival. In untreated maternal infections, maternally transferred protection suppressed para-
sitaemia and reduced pup mortality by 75 per cent compared with pups from naı ¨ve dams. However, when
dams were treated with anti-malarial drugs, pups received fewer maternal antibodies, parasitaemia was
only marginally suppressed, and mortality risk was 25 per cent higher than for pups from dams with
full infections. We observed the same qualitative patterns across three different host strains and two
parasite genotypes. This study reveals the role that within-host infection dynamics play in the ﬁtness con-
sequences of maternally transferred immunity. Furthermore, it highlights a potential trade-off between
the health of mothers and offspring suggesting that anti-parasite treatment may signiﬁcantly affect the
outcome of infection in newborns.
Keywords: passive immunity; neonatal immunology; immunoglobulins; anti-malarial drugs;
Plasmodium chabaudi; maternal effects
1. INTRODUCTION
Maternally transferred immunity constitutes an epigenetic
mechanism by which mothers transmit their history of
pathogen exposure to protect offspring during the develop-
ment of their own immune system [1]. Maternally
transferred immunity is, therefore, an important source
of phenotypic variation [2]. It can affect the expression of
traits in subsequent host generations and hence underlie
variation in resistance to parasites [3]. However, levels of
antibodies in adults can vary both quantitatively and quali-
tatively over the course of infection [4]. To date, few
studies have investigated how the factors affecting the
dynamics of maternal infection and the resulting immune
response might affect the strength and the speciﬁcity of
protection transferred to offspring. More broadly, variation
in the dynamics of maternal infection is a novel experimen-
tal framework to study trans-generational responses to
environmental heterogeneity and the maintenance of
inter-individual variability. As such, maternally transferred
immunity can inﬂuence how organisms are shaped by the
interactions between genetic and ecological factors [3,5].
However, these two factors—the dynamics of infection
and host genetics—have largely been overlooked in studies
of maternally transferred immunity.
There is nevertheless good reason to hypothesize that
the dynamics of maternal immunity may vary over time.
Theoretical [6,7], experimental [4,8] and epidemiological
[9] studies show that the duration of infection in adults
inﬂuences the amount and the diversity of antibodies pro-
duced by the immune response, thereby affecting the level
of protection that could potentially be transferred. This is
because the length of infection determines the range, dur-
ation and amount of antigen expression by parasites
[4,10]. In addition to host and parasite characteristics
(such as parasite virulence, concurrent and previous
infections, infectious doses, age, sex and condition of
hosts), antiparasitic drug treatment can inﬂuence infec-
tion duration. Consequently, by decreasing the duration
of expression, or the range and amount of antigens
expressed by parasites, anti-parasite drugs may negatively
affect the effectiveness of an immune response [11].
Alternatively, it has also been hypothesized that treatment
against parasites could enhance immune responses by
altering the different parasite proteins accessible to the
host [12,13] and result in a stronger or more directed
response. The effect of drug treatment on the acquisition
of immunity is particularly important to consider for indi-
viduals living in endemic areas, where re-infection is likely
to occur and anti-parasite drug treatment is widely used.
Furthermore, in endemic areas, offspring are likely to be
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age where their immune system is not fully developed
[14]. They consequently rely on the repertoire of anti-
bodies transferred by their mothers to confer passive
protection. There may, therefore, be consequences of
maternal anti-parasite treatments for the transfer of
passive immunity to offspring.
Rodent malaria is an excellent model system to test
how infection dynamics and host and parasite genetics
interact to shape the protection provided by maternally
transferred immunity. Different lines of inbred mice dis-
play different patterns of immune responses [10,15], a
bank of genetically characterized parasite genotypes are
available and infection dynamics can be manipulated
using anti-malarial drugs to curtail the duration of the
infection [16]. Previous studies of maternally transferred
immunity to rodent malaria have established that varying
levels of resistance to malaria infection could be trans-
ferred to offspring by antibodies in milk [17–19].
However, while there are many studies on the impli-
cations of malaria contracted by the mother during
pregnancy [20], very little is known about factors inﬂuen-
cing immune responses of the mothers and transferred
immunity, especially when mothers are exposed before
pregnancy. Moreover, in the few studies there are, infec-
tions in dams were either self resolving or manipulated
to boost acquired immunity [21], e.g. up to three con-
secutive short drug-treated infections. It is, therefore,
unclear how the dynamics of maternal infection, standard
treatment protocols and associated immune responses
may affect maternally transferred immunity. Here, we
examine, in three different mouse strains, the conse-
quences of drug treatment for the transfer of maternal
antibodies and the health (growth rate, parasitaemia
and anaemia) and ultimate survival of offspring. This
allowed us to test whether pups born to dams that experi-
enced malaria infection were better protected than pups
from naı ¨ve dams and whether the maternal transfer of
protection is substantially decreased when drugs are
used to cure infections in dams and consequently alter
the infection dynamics.
2. METHODS
We experimentally tested whether the dynamics of maternal
infection inﬂuenced the protection conferred by maternally
transferred immunity. For three different mouse strains, we
infected dams with malaria and bred from them. Dams
were either drug-treated three weeks post-infection,
untreated with the infection allowed to run its full course
or sham-infected as a control. Their pups were infected
with one of two parasite genotypes that differ in virulence,
or sham-infected. We measured the amount of maternally
transferred antibodies and the morbidity and mortality
experienced by pups.
(a) Parasites and hosts
We used three different strains of mice: two strains of inbred
mice C57Bl/6 and BalbC, and one strain of outbred mice
MF1 (Harlan Scientiﬁc, UK). C57Bl/6 differ from BalbC
mice in that BalbC mice aremore‘Th2’ prone (with emphasis
in the production of antibodies) and C57Bl/6 more ‘Th1’
prone (with emphasis on the cellular immune response).
Mice were housed at 218C with a 12 h light cycle, and
maintained on a diet of SDS41B food pellets (Harlan
Scientiﬁc, UK) and 0.05 per cent para-aminobenzoic acid-
supplemented drinking water to facilitate parasite growth
[22,23]. We used two different genotypes of Plasmodium
chabaudi that differ in virulence; AS and DK (WHO Registry
of Standard Malaria Parasites, The University of Edinburgh).
In adult mice, AS causes greater weight loss and anaemia than
DK, and in particularly, sensitive mouse strains, such as
BalbC, AS might cause some mortality [24], but see Mideo
et al.[ 25]. The parasite genotypes were originally cloned
from wild parasite isolates from thicket rats in the Central
African Republic [26]. All infections (of dams and pups)
were initiated with 0.1 ml citrate saline solution containing
10
6 parasitized red blood cells (RBCs). Sham-(control)
infected mice received only citrate saline.
(b) Dams and breeding
For each host strain, 20 dams were infected at nine weeks of
age with genotype AS, and an additional 10 dams were sham
infected to generate controls. All infected dams developed
malaria; conﬁrmed by examining blood smears on 4 days
post-infection. At 21 days post-infection, half of the infected
dams from each strain were randomly selected and treated
with 70 mgm l
21 pyrimethamine in their drinking water for
4 days to cure infections. As peak parasitaemia occurs 6–8
days post-infection, parasitaemia has dropped to very low
levels by day 21, and the immune response has reached a pla-
teau [27–29]. Females were not sampled for blood after drug
treatment to reduce disturbance in their reproductive cycles
prior to mating. However, previous work has demonstrated
that a 4 day treatment of pyrimethamine clears mice from
remaining parasites [16]. One month after infection, all
dams were exposed to male bedding to induce oestrus and
then paired with males (three dams per male, one dam, ran-
domly chosen, for each of the treatment groups). After two
weeks, males were removed and dams were put in individual
cages. Dams were sampled to measure antibody levels (see
below) just after weaning of their pups (to avoid disturbance
during pregnancy and lactation).
Ofthe30damsforeachhoststrain,52gavebirthto5.61+
1.18 pups on average (17 C57Bl/6 dams, 13 BalbC dams and
22 MF1 dams; table 1). Five pups died before weaning at 18
days old (see below), all from MF1 females with more than
11 pups (two from control dams, two from dams infected
and drug-treated and one from an infected dam). The
number of pups in the litter differed according to mouse
strain (nfemales ¼ 52, npups ¼ 387; DAIC (Akaike information
criterion) to the closest model (mouse strain   maternal
treatment) ¼ 3.01, p ¼ 0.0023), with MF1 mothers giving
birth to signiﬁcantly more pups (4.24 more+0.29) than the
two other mouse strains that did not differ signiﬁcantly
(C57Bl/6 6.58+0.61 and BalbC 5.61+0.59 pups per
dam). The ranges of litter sizes were four to nine pups for
C57Bl/6 dams, 6–11 pups for BalbC and 6–13 pups
for MF1. Once corrected for mouse strain, litter size did not
differ according to sire identity (DAICc to the model with
mouse strain only ¼ 13.1, p ¼ 0.30).
At 10 days old, pups were individually marked with a non-
toxic marker pen and their identiﬁcation was maintained
throughout the experiment. Pups were weighed at 10 and
18 days old to test whether growth rate varied across strains.
For pup weight at 10 days old, there was a non-signiﬁcant
borderline effect of maternal treatment (nfemales ¼ 52,
npups ¼ 382; DAIC to closest model (null model) ¼ 1.85,
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host strain (nfemales ¼ 52, npups ¼ 382; DAIC between
model with host strain and maternal treatment and model
with maternal treatment ¼ 3.25, p ¼ 0.095). For pup
weight at 18 days, only mouse strain had a signiﬁcant effect
(nfemales ¼ 52, npups ¼ 382; DAIC to closest model (strain
and maternal treatment effect) ¼ 4.71, p ¼ 0.013), MF1
pups being 1.76+0.48 heavier than the other mouse
strains). In summary, MF1 mothers had more pups that
grew faster, but no signiﬁcant effect of maternal treatment
on pup weight or growth was detected.
(c) Pup infections and sampling
At approximately 18 days old (17.75+0.06 days; range
17–19 days), all pups were separated from their mothers
for weaning. One day after weaning, pups from each litter
were divided randomly into three treatment groups: infected
with AS, infected with DK or sham infected and infections
were initiated for the sample sizes shown in table 1. Pups
of the same family and of same sex were kept together and
split in two groups when their number exceeded six individ-
uals (this is the maximum recommended density for our
cages). To minimize the amount of blood collected from
each pup, individuals were either sampled for immunological
assays (at weaning n ¼ 151 pups) or for RBC counts and thin
smears (n ¼ 231 pups). The RBC/smear group was split in
two cohorts; each individual was sampled every second day
between days 4 and 30 post-infection (no pups died before
day 4). RBC density was measured by using ﬂow cytometry
(Beckman Coulter). Thin blood smears prepared from tail
blood were Giemsa stained and microscopically analysed
( 1000 magniﬁcation) to calculate the proportion of
parasitized RBCs.
(d) Immunological assays
To measure parasite-speciﬁc antibodies in mothers and
pups, enzyme-linked immunosorbent assays were perfor-
med. Plates (Immunosorb, NUNC) were coated with 50 ml
of 1 mgm l
21 solution of P . chabaudi AS MSP1 antigen
freeze–thawed crude lysate (plasmid kindly provided by
J. Langhorne) in carbonate buffer. The plates were coated
overnight at 48C and the wells were blocked with 5 per cent
bovine serum albumin (Sigma) in carbonate buffer for 2 h at
378C. Each serum sample was assayed in a series of duplicate
dilutions from 1:100 to 1:12800 and incubated for 1 h at
378C. Antibody binding was detected using horseradish
peroxidase-conjugated anti-murine IgG2a (Southern Biotech
1080 05) at concentration 1:4000 for MF1 and BalbC and
1: 200 for C57Bl/6 (different IgG2a isotype) and ABTS
peroxidase substrate (Sigma). Samples were read at 405 nm,
and optical density (OD) log-transformed for normality.
(e) Statistical analysis
Using R statistical software [30], a series of ANOVA/ANCOVA
and mixed-effects models (linear mixed models and general-
ized additive mixed models (GAMM)) was constructed
(table 2). When required, we included cage nested within
dam identity as a random effect and, to take repeated measures
on pups into account, pup nested within cage and dam.
Table 1. Sample sizes according to mouse strain, maternal treatment and pup treatment.
mouse
strain
maternal
treatment
number
of dams
mean
litter size
pup
treatment
total number
of pups
pups sampled to
survey RBC counts
pups sampled for
immune assays
C57Bl/6 control 7 6.57 control 15 6 9
DK 14 11 3
AS 17 11 6
infected and cured 3 7.33 control 5 3 2
DK 7 6 1
AS 10 6 4
infected 7 6.28 control 9 5 4
DK 17 12 5
AS 18 12 6
total 17
BalbC control 6 5.00 control 6 5 1
DK 11 10 1
AS 13 10 3
infected and cured 3 6.00 control 4 3 1
DK 6 5 1
AS 8 6 2
infected 4 6.25 control 5 3 2
DK 9 6 3
AS 11 6 5
total 13
MF1 control 7 8.71 control 16 7 9
DK 22 13 9
AS 23 14 9
infected and cured 7 9.57 control 18 7 11
DK 24 14 10
AS 25 14 11
infected 8 9.25 control 23 7 16
DK 25 14 11
AS 26 14 12
total 22
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(library lmer) with survival as a binary-dependent variable.
Terms ﬁtted in the models included pup sex, pup treatment,
maternal treatment, mouse strain and their interactions. The
parsimony of the null and of alternative models were assessed
in an ANOVA setting using AIC or second-order AIC (AICc),
when the ratio between sample size and the number of par-
ameters tested was below 40 [31]. We report the DAIC or
DAICc between the most parsimonious model and the closest
model and the probability associated with the likelihood ratio
test from the comparison of these models. When interactions
were signiﬁcant, we analysed the data for each level of relevant
variables, and we report post hoc test results. Means and
effects are reported+one standard error.
3. RESULTS
(a) Effect of maternal drug treatment: maternal
transfer of antibodies
While the antibody levels of dams when pups were weaned
were strongly affected by the interaction of maternal treat-
ment and mouse strain (nfemales ¼ 52, DAICc with the
closest model (mouse strain and maternal treatment) ¼
3.26, p ¼ 0.014; ﬁgure 1), maternal treatment had a sig-
niﬁcant effect in all strains (p , 0.01). Control dams had
signiﬁcantly lower antibody levels than infected dams in
all cases; in MF1 and C57Bl/6 mice, drug-treated dams
had signiﬁcantly lower levels than untreated infected
dams; ﬁgure 1). In BalbC females, drug-treated dams
were not signiﬁcantly different from untreated infected
dams (mean difference b ¼ 20.23+0.25, p ¼ 0.54).
Once corrected for maternal treatment, C57Bl/6 mice
had antibody levels that were 0.45+0.15 units lower
than the other two strains with no signiﬁcant difference
between BalbC and MF1 females.
As expected, control dams and their pups had no
speciﬁc anti-malaria antibodies (ﬁgure 2). In infected
dams (both treated and untreated), antibody levels of
the pups at weaning were strongly correlated with their
mothers’ levels (nfemales ¼ 26, npups ¼ 86; DAIC to null
model ¼ 43.1, p , 0.0001; ﬁgure 2). The strength of
the relationship was not signiﬁcantly inﬂuenced by
maternal treatment (nfemales ¼ 26, npups ¼ 86; DAIC
between the model with the interaction maternal
treatment   pup antibody level and the model with only
pup antibody level ¼ 2.53, p ¼ 0.19, buntreated females ¼
1.05+0.12; btreated females ¼ 1.01+0.15). Pup antibody
levels were very repeatable within each litter (model
with female as ﬁxed effect: nfemales ¼ 26, npups ¼ 86;
DAIC to null model ¼ 136.3, p , 0.0001). Therefore,
because not every pup could be sampled to determine
antibody levels, we used maternal antibody level as the
level of antibody transferred to a pup.
(b) Effect of maternal drug treatment: survival
of pups
All pups survived infection with DK, regardless of
maternal treatment. By contrast, there was variation in
the mortality rate of infections with the more virulent
clone, AS. The survival of pups exposed to AS was
signiﬁcantly different according to maternal treatment
(nfemales ¼ 52, npups ¼ 151; AIC ¼ 53.4, DAIC to null
model ¼ 23.6, p , 0.0001; ﬁgure 3). Model estimates
indicate that survival probability was the lowest for
pups from control mothers (0.16+0.084), then from
drug-treated mothers (0.77+0.092), and pups from
Table 2. List of the different variables tested, and ﬁxed and random effects used to build the models tested.
variable tested ﬁxed effects tested
random effects
included in the model more parsimonious model
antibody levels of dams
when pups were
weaned
mouse strain, maternal
treatment
interaction mouse
strain   maternal treatment;
ﬁgure 1
antibody levels of pups at
weaning (pups from
infected dams)
mouse strain, maternal levels
of antibody, maternal
treatment, pup sex, (‘dam’
effect to test intra-litter
repeatability)
cage effect nested in
dam effect
maternal levels of antibody;
ﬁgure 2, dam
pups survival pup parasite genotype,
maternal treatment,
mouse strain, pup sex
cage effect nested in
dam effect
pup parasite
genotype   maternal
treatment; ﬁgure 3
pups parasitemia 4 days
post-infection
pup parasite genotype,
maternal treatment,
mouse strain, pup sex
cage effect nested in
dam effect
pup parasite
genotype   maternal
treatment, mouse strain;
ﬁgure 4
pups daily RBC counts
(anaemia)
GAMM, days post-infection
as smooth term, pup
parasite genotype,
maternal treatment,
mouse strain, pup sex
cage effect nested in
dam effect
pup parasite
genotype   maternal
treatment   mouse strain;
electronic supplementary
material, ﬁgure S1
lowest RBC count pup parasite genotype,
maternal treatment,
mouse strain, pup sex
cage effect nested in
dam effect
maternal treatment   pup
parasite genotype, mouse
strain; electronic
supplementary material,
ﬁgure S2
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(0.99+0.069). All pairwise comparisons were signiﬁ-
cantly different, even between the closest groups, i.e.
pups from drug-treated and non-drug-treated females
(nfemales ¼ 32, npups ¼ 100, DAIC to closest model (null
model) ¼ 2.23, p ¼ 0.017). No signiﬁcant difference in
survival was observed between mouse strains (DAIC
between the model with the interaction mouse strain  
maternal treatment and the model with only maternal
treatment ¼ 2.36, AIC ¼ 69.9, p ¼ 0.061). Furthermore,
among AS-infected pups, survival probability correlated
positively with maternal antibodies, even when corrected
for maternal treatment (nfemales ¼ 52, npups ¼ 151; DAIC
to null model ¼ 2.24, p ¼ 0.038, once controlled for
maternal treatment, survival rate increased by 0.15+
0.038 for each increase of one unit of antibody levels).
(c) Effect of maternal drug treatment: levels of
parasitaemia in pups
We analysed parasitaemia at 4 days post-infection (i.e.
before any pups died of malaria) as this avoids problems
with missing data owing to mortality of the most severe
infections. For pups exposed to AS, parasitaemia (pro-
portion of infected RBC) was signiﬁcantly inﬂuenced by
maternal treatment and mouse strain (npups ¼ 44; DAICc
to closest model (model with maternal treatment only) ¼
2.96, p ¼ 0.039). Once mouse strain was controlled for,
all the maternal treatments differed from each other (esti-
mated mean parasitaemia: pups from control females
0.31+0.046, from females infected and drug-treated
0.10+0.045 and from females infected and not drug-
treated 0.0081+0.033). For pups exposed to DK,
parasitaemia signiﬁcantly differed according to maternal
treatment and mouse strain (npups ¼ 47, DAICc to closest
model (model with maternal treatment   mouse strain
interaction) ¼ 5.26, p ¼ 0.0033). However, once corrected
for strain, parasitaemia of pup infections from control and
drug-treated females differed from infected females but
not from each other (estimated mean parasitaemia: pups
from control females 0.11+0.023, from females infected
and drug-treated 0.089+0.017 and from females infected
and not drug-treated 0.044+0.013).
The overall analysis (on both AS- and DK-infected
pups)indicatedthatthemostparsimoniousmodelinvolves
an interaction between pup treatment   maternal treat-
ment and mouse strain (npups ¼ 139; DAICc to closest
model (model with maternal treatment   pup treatment
interaction) ¼ 6.48, p ¼ 0.0051; ﬁgure 4). This demon-
strates that the patterns described above are comparable
for each mouse strain, but that pups from C57Bl/6 had
parasitaemia lower than the two other strains (mean
difference between C57Bl/6 pups and other pups,
b ¼ 20.042+0.017, p ¼ 0.0152). Finally, in accordance
with the higher virulence of AS, post hoc tests indicated
that, once maternal treatment is controlled for, parasitae-
mia was 0.039+0.012 higher for AS compared with
DK-infected pups (p ¼ 0.026), which were 0.12+0.021
higher than controls (p , 0.0001).
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Figure 1. Speciﬁc anti-malaria (MSP1 antigen) antibody levels of dams at weaning of their pups, according to mouse strain:
(a) C57Bl/6, (b) BalbC, (c) MF1 and maternal treatment. In white, control females; in grey, females exposed to malaria
and drug-treated; in black, females exposed to malaria not treated. Numbers denote sample sizes, error bars 95% CI.
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Figure 2. Correlation at weaning of the pups between speciﬁc anti-malaria (MSP1 antigen) antibody levels of females and their
pups according to maternal treatment and mouse strains: (a) C57Bl/6, (b) BalbC, (c) MF1. White circles are control females,
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Please note that because the antibody levels at weaning were not available for all the pups (see §2), not all the females are
represented in this ﬁgure.
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of the pups
The anaemia experienced by pups, measured as RBC
counts in relation to days post-infection, depends on the
interaction between pup treatment, maternal treatment
and the host strain (GAMM models, npups ¼ 231, DAIC
to closest model (interaction maternal treatment and pup
treatment) ¼ 58.1, p , 0.0001; electronic supplementary
material, ﬁgure S1). To describe this triple interaction in
more detail, we focus on the lowest mean RBC counts
(electronic supplementary material, ﬁgure S2). The day
of lowest RBC count varied between 4 and 10 days post-
infection across treatment groups, reﬂecting different
infection dynamics across maternal treatments (see
GAMMmodelsintheelectronicsupplementarymaterial).
Once corrected for mouse strain (see below), pups from
infected dams had signiﬁcantly higher minimum RBC
counts (for DK-infected pups npups ¼ 38, b ¼ 21.98+
0.42, p , 0.0001; for AS-infected pups npups ¼ 39,
b ¼ 22.89+0.51, p , 0.0001), but pups from dams not
infected or infected and drug cured had similar minimal
RBC counts (for DK-infected pups npups ¼ 32,
b ¼ 20.51+0.45, p ¼ 0.69; for AS-infected pups
npups ¼ 22, b ¼ 20.81+0.53, p ¼ 0.33).
As observed for parasitaemia, lowest mean RBC
counts were affected by the interaction between pup
treatment   maternal treatment and by a simple effect
of mouse strain (npups ¼ 123; DAICc to closest model
(model with maternal treatment   pup treatment
interaction) ¼ 2.73, p ¼ 0.046). This means that the pat-
terns that we have described were comparable for each
mouse strain, except that pups from C57Bl/6 had RBC
counts slightly lower than the two other strains (mean
difference between C57Bl/6 pups and other pups
b ¼ 20.49+0.21, p ¼ 0.044).
4. DISCUSSION
In this study, we investigated the role that within-host
infection dynamics play in the ﬁtness consequences of
maternally transferred immunity. Using rodent malaria as
a model system, we manipulated maternal infection and
compared the levels of antibody transferred to offspring,
and the resulting morbidity and mortality of experimental
infections in pups. Our results clearly show, across three
different host strains and two different parasite genotypes,
that pups born to dams previously challenged with malaria
infection experience lower parasitaemia and are more likely
to survive than pups from naı ¨ve dams. Moreover, our
results also demonstrate that maternal transfer of protec-
tion is substantially decreased when drugs were
administered at three weeks post-infection to cure dams.
Drug treatment against malaria reduced the amount of
antibody transferred, resulting in higher parasitaemia
infections in pups and reduced survival probability com-
pared with pups from infected dams that were not treated.
(a) Maternal immunity and protection of the pups
Our results indicate a correlation between the levels of
maternally transferred immunity and the protection con-
ferred to the pups. Maternal exposure to malaria had a
positive effect on the survival of pups to infection.
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strain), to mouse strain: (a) C57Bl/6, (b) BalbC, (c) MF1 and maternal treatment. In white, pups from control females;
in grey, from females exposed to malaria and drug-treated; whereas in black, from females exposed to malaria not
treated. Numbers denote sample sizes, error bars 95% CI. NB: all the control pups (sham infected) had no parasites
(0% parasitaemia).
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tion conferred to the pups, measured in terms of
enhanced survival, is correlated with the amount of anti-
bodies received (even after controlling for maternal
treatment). Several studies [32–36] (but see Williams
et al.[ 37]) have shown that an immune challenge might
affect maternal condition, feeding rate and consequently
reproductive success of breeding animals. The cost of
mounting an immune response and coping with malaria
infection may indeed affect post parental care [38] and
prenatal maternal effects [39]. However, in our exper-
iment, while maternal exposure to malaria affected
pregnancy rates, it did not decrease the weight or
growth rate of the pups, and had a positive effect on the
survival of challenged pups. Experimental manipulations
of the amount of antibodies transferred to the pups are
now required to test the link we observe between mater-
nally transferred antibodies and offspring survival
[40,41]. An alternative hypothesis to explain the transfer
of protection from mothers exposed to malaria is that
maternally transferred immune complexes ‘prime’ the
immune response of pups. May et al. [42] have recently
observed, in humans, an antibody-dependent trans-
placental transfer of an antigen in the form of immune
complexes that could prime the immune system of the
young (but see Soulard et al.[ 43] and Malhotra et al.
[44]). Disentangling pre- and post-natal effects of mater-
nally transferred immunity and priming of the offspring
immune system is challenging, but rodent malaria
models offer a number of useful tools. This includes the
experimental manipulation of maternal infection (as we
have demonstrated here) [45], cross-fostering manipula-
tions [19,46,47], the use of different mouse strains that
vary in the characteristics of their immune responses
[15] and cross-breeding of mouse strains to distinguish
between maternally transferred antibodies and antibodies
produced by pups [21].
(b) Effect of maternal drug treatment
The dynamics of infection can have major effects on the
morbidity and mortality risk of infection in adults [8], but
the consequences for offspring remain largely unknown
because it has rarely been manipulated experimentally
[4,8]. By shortening the duration of infection experienced
by adults, drug treatments can negatively affect the breadth
o ft h ei m m u n er e s p o n s eb yr e d u c i n gt h er a n g ea n dt h e
amount of antigens expressed by the parasite [11]. Alterna-
tively, it is possible that drug treatment can render different
parasite proteins accessible to the host immune system,
inducing quantitative and qualitative changes in antigen
recognition, which could include antigens not exposed by
parasites under normal conditions [12,13]. Testing these
hypotheses requires data on the afﬁnity and avidity of
maternal antibodies to parasite antigens exposed during
infections in offspring. It, therefore, remains unclear
whether, in adults, a protective response is induced after
treatment against parasites, how it differs from acquired
immunity to ‘natural’ infection [48,49] and how this affects
levels of protection conferred to offspring [50].
Studies performed in natural conditions suggest that
exposure to parasites is correlated with the amount of
antibodies transferred [51–53] to offspring and that the
inter-annual pattern of exposure to parasites affects the
transfer of a protective repertoire of antibodies [54,55].
However, experimental manipulation of the dynamics of
maternal exposure is needed to test the consequences of
maternalexposurefor thetransferofprotection.Our results
showthatshorter maternal infections inducelessprotection
for offspring than full infections. Moreover, drug
treatment—even towards the end of the acute phase of
infection—curtails infections enough to reduce maternally
transferred protection. More broadly, our results highlight
that treating maternal infection as a presence/absence
factor is not sufﬁcient to evaluate the adaptive value of this
maternal effect in natural conditions [3]. Future studies
should focus on testing how the length of infection interacts
with other characteristics of maternal infection (such as
timingoftheinfection,infectiousdoseandinfectiongenetic
diversity)toshapethe amountofantibodiestransferredand
the level of protection conferred to offspring. These exper-
iments could also distinguish two alternative hypotheses;
shortened maternal exposure to parasites enhances
maternal condition and consequently offspring ﬁtness, or
it decreases maternally transferred immunity and ﬁtness of
the young if it is exposed to parasites.
(c) Effect of mouse strain
Inbred mouse strains differ in key characteristic of the
immune response. For example, BalbC mice are more
‘Th2’ prone (and therefore emphasizing the production
of antibodies) and C57Bl/6 more ‘Th1’ prone (and there-
fore emphasizing the cellular immune response).
Immunity to blood-stage malaria infections involves both
antibody-dependent and independent mechanisms, and
T-cellsplayacrucialroleintheinductionandmaintenance
of this immunity [56]. After an initial Th1 response
required to control the acute infection [57–59], mice
develop a Th2 response with subsequent B-cell activation,
producing antibodies [60]. Despite the differences in the
Th1- and Th2-oriented immune responses of BalbC and
C57Bl/6 strains, Helmby et al. [61] have shown that both
strains develop anti-malarial IgG at a similar rate and
magnitude after repeated exposures to malaria [61]. As
maternal immunity relies on the production of antibodies,
we tested if the difference in the initial orientation of
maternal immune responses of C57Bl/6 and BalbC strains
might affect the protection transferred to the pups. Our
results indicate that the protection conferred to the pups
isaffectedinthesamewaybydifferentmaternaltreatments
across C57Bl/6, BalbC and an outbred strain (MF1).
However, while qualitative patterns matched, C57Bl/6
pups had overall lower parasitaemia, slightly lower RBC
counts (even for control pups) and the C57Bl/6 dams pro-
duced and transferred less antibodies to their pups. This
latter result canpotentially beexplained bya Th1-oriented
immune response of this mouse strain but lower RBC
counts, observed even for control pups, are not usually
described for this mouse strain [62] even though only
data on adults are available. More detailed data on the
dynamicsofinfectionsinpups,coupledwithmathematical
modelling will help reveal the mechanisms underpinning
strain variation in infection dynamics.
(d) Conclusions
Our results show that anti-parasitic treatments are powerful
tools to manipulate the dynamics of maternal infection and
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offspring. We observed the same pattern—that drug treat-
ment of dams reduces maternally transferred immunity to
pups—across three different mouse strains and after expos-
ing pups to different parasite genotypes. Explaining the
impact of infection dynamics and genetic background on
the protection conferred by the mother is a key factor
underpinning inter-individual [3] and interspeciﬁc [63]
variability of maternally transferred immunity observed in
natural conditions. More broadly, understanding these
relationships may be important for the design of public
health policies. Given the inconclusive evidence on the
effect of maternal treatment on human infants’ survival of
malaria infection [50] and immune response [44], our
results highlight the need to investigate this issue. The
effect of treatment on the acquisition of immunity is par-
ticularly important for individuals in endemic areas where
re-infection is likely to occur and treatment against parasitic
disease is widely used. In these endemic areas, infants are
likely to be exposed to the same diseases as their parents
and at an age when their immune system is not fully devel-
oped. They consequently rely on the repertoire of
antibodies transferred by their mothers to confer passive
protection. However, as maternal treatment against para-
sites substantially decreases the amount of antibodies
transferred, resulting in higher parasitaemia infections in
pups and reducing their survival probability, we reveal
potential trade-off between maximizing the health of
mothers and offspring.
All procedures were carried out in accordance with the UK
Animals (Scientiﬁc Procedures) Act 1986.
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